Search

Your search keyword '"Borchmann, Sven"' showing total 69 results

Search Constraints

Start Over You searched for: Author "Borchmann, Sven" Remove constraint Author: "Borchmann, Sven" Database Unpaywall Remove constraint Database: Unpaywall
69 results on '"Borchmann, Sven"'

Search Results

1. Procarbazine-induced Genomic Toxicity in Hodgkin Lymphoma Survivors

2. Plasma Circulating Tumor DNA Sequencing Reveals the Landscape of Acquired Mutations in Patients with Hepatocellular Carcinoma: a Potential Predictive Value in Liquid Biopsy

3. Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR

4. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

5. S236: HIGH-BREADTH SEQUENCING OF CIRCULATING TUMOR DNA IDENTIFIES NOVEL CLASSIFICATION OF HODGKIN LYMPHOMA

7. P1209: PERIPHERAL BLOOD CTDNA-SEQUENCING ENABLES PREDICTION OF OUTCOMES IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING A DYNAMIC RISK MODEL

9. Supplementary Tables from Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer

10. Supplementary Figures from Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer

11. Data from Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer

12. Data from Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer

13. Supplementary Tables from Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer

14. Supplementary Figures from Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer

16. Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing

17. JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)

19. P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma

21. Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors

23. Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment

27. Abstract LBA010: Therapeutic stimulation of nucleic acid receptor RIG-I enhances efficacy of kinase inhibitor treatment in oncogene-driven tumors

28. Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)

29. In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection

30. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma

31. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I

32. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial

36. Exhaustive circulating tumor DNA sequencing reveals the genomic landscape of Hodgkin lymphoma and facilitates ultrasensitive detection of minimal residual disease

38. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

43. Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC

44. Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma

47. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma

49. Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment

Catalog

Books, media, physical & digital resources